Lilly and Sankyo To Collaborate on Novel Oral Antithrombotic Compound

21-Dec-2000

Eli Lilly and Company (NYSE: LLY and TSE: 4857) and Sankyo Company, Ltd. (TSE: 4501), announced they have signed a letter of intent to collaborate on CS-747, a potentially potent antiplatelet agent that blocks ADP receptors. CS-747 is being tested in Phase I human clinical trials for its ability to prevent blood clotting in the coronary artery. The novel oral compound was discovered by Sankyo and Ube Industries, Ltd. (TSE: 4208), and will be developed for the secondary prevention of thrombotic cardiovascular complications in patients with a recent ischemic stroke or with acute coronary syndromes (unstable angina and myocardial infarction). CS-747 will also be developed for reducing secondary complications, including death, recurrent myocardial infarction, recurrent stroke and rehospitalization for severe angina.

Acute coronary syndromes develop in about 2.5 million patients annually, and over the next decade, this number is expected to grow to nearly 4 million per year on a global basis. Even with recently approved treatments, up to 35 percent of these patients will suffer death, myocardial infarction or recurrent angina in the subsequent 12 months. Ischemic stroke also remains a leading cause of death and permanent disability. Over the next 10 years, the market size for chronic antiplatelet therapy following ischemic stroke will approach an estimated 5.5 million patients. Lilly and Sankyo anticipate this potentially potent antiplatelet agent could represent a major advance over currently available compounds.

Under the letter of intent, Sankyo will receive a signing fee, milestone payments and royalties on product sales. Lilly and Sankyo will co-promote the product in the United States. For the remaining global market, Lilly and Sankyo will jointly market the product except for certain countries where Lilly will receive exclusive sales and marketing rights. Lilly and Sankyo will share in the development of the compound and plan to manufacture the finished product. Ube will manufacture the bulk material.

"This collaboration reinforces our commitment to cardiovascular research and expands our growing portfolio of antithrombotic compounds," said August M. Watanabe, M.D., executive vice president, science and technology, for Lilly. "We are looking forward to a long and productive relationship with Sankyo, a company widely recognized for its cardiovascular expertise and innovation."

"We are excited to have the opportunity to work in close collaboration with Lilly on this important cardiovascular product," said Tetsuo Takato, president at Sankyo. "Our joint efforts to co-develop CS-747 will help advance this important therapeutic discovery. We’re eager to make this compound available as quickly as possible to the many physicians and patients who require it. By combining our long-standing research and development expertise and our substantial marketing experience with that of Lilly, we are ensuring that we are more efficiently expediting the delivery of this compound."

https://www.chemeurope.com/en/news/565/lilly-and-sankyo-to-collaborate-on-novel-oral-antithrombotic-compound.html